Chiesi bets $160M on Gos­samer Bio’s make-or-break late-stage PAH drug

Gos­samer Bio has lined up a part­ner to foot the de­vel­op­ment and com­mer­cial­iza­tion bill for its make-or-break late-stage drug, ex­pand­ing Phase 3 plans and paving …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER